{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:16:00Z","timestamp":1759342560836},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,17]],"date-time":"2006-07-17T00:00:00Z","timestamp":1153094400000},"content-version":"vor","delay-in-days":4043,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[1995,6,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study examined the sensitivity and specificity of serum auto\u2010antibodies to p53 protein as a non\u2010invasive marker of p53 genetic alterations or protein accumulation in lung cancer cases. A sensitive ELISA to detect serum p53 antibodies was developed and used to examine sera from 186 patients undergoing pulmonary surgery for a suspected lung cancer. Target antigens in ELISA were wild\u2010type p53 protein and 5 peptides covering the N\u2010 and C\u2010terminal parts of the protein. Sixteen sera were positive for serum p53 antibodies in both ELISAs and all were among the 136 patients with confirmed primary lung carcinoma. Of 50 patients with other pulmonary diseases, none had p53 antibodies. In 92 cancer patients exons 5 to 8 of the p53 gene were examined for mutations by denaturing gradient gel electrophoresis and direct sequencing of PCR products. Forty\u2010seven tumours had a p53 mutation and 7 (15.2%) of these were positive for p53 antibodies. Two patients had serum antibodies but no detectable mutation in exons 5 to 8. Frequencies of p53 mutations and serum antibodies were higher in squamous cell carcinoma patients than in adenocarcinoma. Accumulation of p53 protein in tumour tissue was observed in 32 patients, but only 5 were positive for p53 antibodies. In conclusion, serum p53 antibodies were detected only in a proportion of lung cancer cases, but the majority were specifically associated with a detectable p53 mutation in the tumour. \u00a9 1995 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.2910640306","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T01:09:13Z","timestamp":1171933753000},"page":"176-181","source":"Crossref","is-referenced-by-count":51,"title":["p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue"],"prefix":"10.1002","volume":"64","author":[{"given":"Christopher Paul","family":"Wild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaret","family":"Ridanpaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sisko","family":"Anttila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Soussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsti","family":"Husgafvel\u2010Pursiainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harri","family":"Vainio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,17]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"315","article-title":"Autoantibodies against the p53 tumor suppressor gene product quantified in cancer patient serum with time\u2010resolved immunofluorometry","volume":"6","author":"Angelopoulou K.","year":"1993","journal-title":"Cancer J."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92354-I"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910390211"},{"key":"e_1_2_1_5_1","first-page":"135","volume-title":"Techniques in diagnostic pathology","author":"Chapot B.","year":"1991"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8023157"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910300404"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.8.3439"},{"key":"e_1_2_1_9_1","first-page":"203","article-title":"High levels of p53 protein in UV\u2010irradiated normal human skin","volume":"8","author":"Hall P. A.","year":"1993","journal-title":"Oncogene"},{"key":"e_1_2_1_10_1","first-page":"3551","article-title":"Database of p53 gene somatic mutations in human tumors and cell lines","volume":"22","author":"Hollstein M.","year":"1994","journal-title":"Nucl. Acids Res."},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1905840"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.2870050202"},{"key":"e_1_2_1_13_1","first-page":"3468","article-title":"Analysis of the anti\u2010p53 antibody response in cancer patients","volume":"53","author":"Labrecque S.","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_1_14_1","first-page":"5872","article-title":"Analysis of p53 antibodies in patients with various cancers define B\u2010cell epitopes of human p53: distribution on primary structure and exposure on protein surface","volume":"53","author":"Lubin R.","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.219"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/358080a0"},{"key":"e_1_2_1_17_1","first-page":"1109","article-title":"Genetic alterations in p53 and K\u2010ras in lung cancer in relation to histopathology of the tumor and smoking history of the patient","volume":"5","author":"Ridanp\u00e4\u00e4 M.","year":"1994","journal-title":"Int. J. Oncol."},{"key":"e_1_2_1_18_1","first-page":"6380","article-title":"The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot","volume":"52","author":"Schlichtholz B.","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.159"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840180313"},{"key":"e_1_2_1_21_1","first-page":"4168","article-title":"Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation","volume":"52","author":"Winter S. F.","year":"1992","journal-title":"Cancer Res."}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.2910640306","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.2910640306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T03:20:23Z","timestamp":1698290423000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.2910640306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,6,22]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995,6,22]]}},"alternative-id":["10.1002\/ijc.2910640306"],"URL":"https:\/\/doi.org\/10.1002\/ijc.2910640306","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,6,22]]}}}